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2012. Supplementary material was identified by a manual examination of litera-
ture. Studies published between 1998 and 2011 were selected using predefined
criteria. Quality of the articles was rated by two independent investigators. Avail-
able data related to resource utilization and costs were extracted and cost units
calculated for Germany. RESULTS: A total of 66 articles were identified. After the
first abstract screening 24 full-text articles were identified as relevant. Finally, after
full-text screening, 10 articles could be included. The majority of studies focused on
the societal economic burden of both impairments. Indirect costs were highest
amongst all cost categories due to productivity loss. Only two identified articles
reported data for Germany. Out of these, one European study transferred survey
data from abroad to the German system and another article reported costs for
specific ophthalmological diseases. CONCLUSIONS: There is a dearth of literature
assessing the economic impact of visual impairment and blindness in Germany
indicating a need for research to fill this gap. Therefore, in a second step, we will
conduct a cost-of-illness study using a bottom-up approach to explore cost units in
detail, as well as their determinants and intangible effects for Germany.
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OBJECTIVES: Psoriasis is a chronic disease that impacts significantly on patients’
quality of life (QoL). Biological drugs interfere in the immunologic process that
triggers and supports psoriasis and, therefore, prove effective in its treatment. The
aim of this study was to perform a cost-utility analysis (CUA) comparing biologic
treatments (adalimumab, etanercept, infliximab, and ustekinumab) in Italy.
METHODS: A decision tree model previously applied to the UK was adapted for
Italy using resource and cost data from the Italian Ministry of Health (Ministero
della Salute). Clinical efficacy in the treatment of moderate to severe psoriasis was
determined by the Psoriasis Area Criteria and Severity Index (PASI). Relative effi-
cacy of biologic treatments was based on a network meta-analysis of clinical trials.
A different level of utility is associated with each level of PASI response. Costs
included hospitalization, drug acquisition, administration, and monitoring over a
10-year time horizon. Incremental cost-effectiveness ratios (ICERs) compared with
supportive care (no systemic therapy) were expressed as euros/quality-adjusted
life year (QALY). One-way sensitivity analyses, where key parameters were
changed to alternative plausible values, explored uncertainty in the results.
RESULTS: In the base case, adalimumab was found to be the most cost effective
compared to supportive care (ICER: €52,583), followed by ustekinumab 90 mg (ICER:
€52,846), ustekinumab 45 mg (ICER: €54,997), infliximab (ICER: €56,141), etanercept
50 mg BIW (ICER: €77,611), and etanercept 25 mg BIW (ICER: €78,194). The ICER for
ustekinumab 90 mg, ustekinumab 45mg, and infliximab compared to adalimumab
were €57,052, €140,445, and €86,794, respectively. Adalimumab remained the most
cost-effective over the vast majority of the one-way sensitivity analyses.
CONCLUSIONS: The analysis demonstrated that adalimumab is the most cost-
effective biologic for the treatment of patients affected by moderate to severe
psoriasis.
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OBJECTIVES: Treatment strategies for the prevention of macular oedema (MO) in
diabetic patients include the postoperative use of steroids with and without anti-
biotics. However, measured with optimal coherence tomography (OCT), between
14% and 22% of diabetic patients still experience postoperative MO, with 3.05%
developing clinically significant MO (CSMO). Nepafenac has recently been granted
approval in Scotland for the licensed indication of reduction in risk of postopera-
tive MO associated with cataract surgery in diabetic patients. The primary objective
was to therefore estimate the incremental cost-effectiveness ratio (ICER) of
Nepafenac compared to the identified standard practice of Prednisolone Acetate
Ophthalmic Suspension (PAOS). METHODS: An Excel-based cost-utility model was
developed with a 90-day time horizon (base-case). An appropriate comparator was
established via consultation with an expert advisory-board comprised of 3 oph-
thalmologists currently practising in Scotland. Effectiveness data were derived
from the pivotal study, C-07-43, whereby the primary outcome demonstrated that
a significantly smaller percentage of patients in the Nepafenac group developed
MO relative to patients in the vehicle group (3.2% vs 16.7%; p0.001). The difference
at 90 days was converted to a RR of MO  0.19. Costs comprised drug acquisition
and outpatient costs, the latter including physician visits and OCT, derived from
ISD Scotland and the BNF 63. Importantly, costs were only associated with those
patients with clinically diagnosed MO. In terms of utilities, an algorithm associat-
ing logMAR visual acuity (VA) with health-related utility estimated with TTO was
used to populate the model. RESULTS: Nepafenac had an ICER of £6,552 per QALY
compared to PAOS in the base-case scenario. CONCLUSIONS: Nepafenac is highly
cost-effective compared to Prednisolone Acetate, and with a concomitant low bud-
get impact (estimated annual maximum of £110,500), should be considered as the
primary treatment for reduction in risk of postoperative MO associated with cata-
ract surgery in diabetic patients.
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OBJECTIVES: Up to 21% of adults will develop tinnitus, manifesting the perception
of a noxious disabling internal sound. Many different treatments are offered, but
evidence on their effectiveness and cost-effectiveness is scarce or absent. Recently,
the effectiveness of a specialised treatment of tinnitus based on cognitive behav-
ioural therapy was demonstrated (Cima et al., 2012). The present study evaluates
the cost-effectiveness of this treatment compared to care as usual, in an audiolog-
ical centre. METHODS: An economic evaluation was carried out alongside a ran-
domized controlled clinical trial. The economic evaluation was conducted from a
societal perspective, using a one-year time horizon. The incremental cost effective-
ness ratio (iCER) was calculated by dividing the difference in costs by the difference
in Quality Adjusted Life Years (QALYs) based on the HUI Mark III. Non-parametric
bootstrapping and sensitivity analyses were used to asses the uncertainty in costs
and effects. Sensitivity analysis included a complete cases analysis and analysis on
data were missing values on the HUI mark III were imputed based on a mixed
regression model from the clinical effectiveness analysis. RESULTS: Compared to
patients receiving usual care, patients who received specialised care gained on
average 0.015 QALYs (BCI:-0.028-0.055) The incremental costs from a societal per-
spective are €286 (BCI:-€828-€1427). The incremental cost per QALY from a societal
perspective amounted to €19,688. The probability that SC is cost-effective from a
societal perspective is 57% for a willingness to pay for a QALY of €35,000.
CONCLUSIONS: Specialised multidisciplinary tinnitus based on cognitive behav-
ioural therapy is cost-effective as compared to usual care. Although uncertainty
surrounding the incremental costs and effects is considerable, sensitivity analysis
indicated that cost-effectiveness results were robust.
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OBJECTIVES: Etanercept, infliximab, ustekinumab, and adalimumab have been
granted marketing authorization for the treatment of moderate-to-severe psoriasis
in Germany. The objective of this study is to evaluate cost-effectiveness of biologic
treatments from the German Social Health Insurance (SHI) perspective.METHODS:
A simple decision model was constructed to assess the cost-effectiveness of bio-
logics compared to supportive care for the treatment of moderate-to-severe psori-
asis over a one-year time horizon. Clinical efficacy was based on the relative prob-
abilities of achieving PASI75, and PASI 90 response obtained via a network meta-
analysis. Weight-based dosing was assumed for infliximab and ustekinumab.
Costs were assessed in terms of 2012 euros, and included drug acquisition, admin-
istration, laboratory tests, clinic visits, and hospitalization costs. Cost-effective-
ness from payer perspective was assessed as the cost-per-PASI75 response and
cost-per-PASI90 response compared with supportive care (no systemic therapy)
over a one-year time horizon. One-way sensitivity analyses, where key parameters
were changed to alternative plausible values, explored uncertainty in the results.
RESULTS: In the base case, adalimumab was found to be the most cost-effective
compared to supportive care (€25,378 per PASI75 responder and €46,870 per PASI90
responder), followed by infliximab (€30,719 per PASI75 responder and €47,300 per
PASI90 responder), ustekinumab (€31,953 per PASI75 responder, and €57,852 per
PASI90 responder), etanercept 50mg BIW (€43,049 per PASI75 responder and
€101,306 per PASI90 responder), and etanercept 25 mg BIW (€43,156 per PASI75
responder and €111,369 per PASI90 responder). The incremental cost per PASI 75
responder gained and the incremental cost per PASI 90 for infliximab compared to
adalimumab were €51,812 and €48,112, and €87,942 and €106,911 respectively for
ustekinumab. Adalimumab remained the most cost-effective over the vast major-
ity of the one-way sensitivity analyses. CONCLUSIONS: This study found that ada-
limumab is the most cost-effective biologic treatment for moderate to severe pso-
riasis from the German SHI perspective.
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OBJECTIVES: Atopic dermatitis (AD) affects more than 15% of the population car-
rying a heavy burden in developed countries and leading to significant losses in
patients’ quality of life, especially in children. Although no cure has yet been found
for AD, novel drugs such as tacrolimus have been released in recent years. There-
fore this study aimed to perform a cost-effectiveness analysis comparing tacroli-
mus 0.1% ointment with ciclosporin 100mg for the treatment of moderate to severe
AD from the Portuguese societal perspective. METHODS: An individual simulation
event process was designed to mimic the natural course and treatment of the
disease, including relapse and maintenance phases. Time to remission and time to
relapse were simulated according to data from a 6-week randomised trial between
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tacrolimus and ciclosporin, and a randomised study which assessed tacrolimus’
relapse prevention ability. Azathioprine and psoralen-UVA were considered as res-
cue therapies after failure of tacrolimus or ciclosporin. Effectiveness was measured
in quality-adjusted life years (QALY) and life years in remission (LYr). Only direct
costs (drugs, medical visits, hospitalization, adverse event treatment and monitor-
ing) were incorporated. The main source for unit costs was the Portuguese National
Health System price list whilst utilities were based on a survey conducted with DA
patients. Time horizon was fixed at 1 year. Probabilistic sensitivity analysis was
conducted with Monte Carlo simulations. RESULTS: For each 100 patients treated
with tacrolimus instead of ciclosporin, mean gains of 0.99 QALY (95%CI: [0.98; 1.00])
and 2.76 LYr (95%CI: [2.72; 2.81]) were estimated. Additionally, tacrolimus utiliza-
tion leads to an overall cost reduction of 16,277€ (95%CI: [-17,619; -15,607]) thus
representing a dominant option. CONCLUSIONS: When compared against
ciclosporin, tacrolimus is a cost-saving and more effective therapeutic option for
the treatment of moderate to severe AD from the Portuguese societal perspective.
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OBJECTIVES:Atopic dermatitis (AD) is a chronic inflammatory itchy skin condition.
In a recent Spanish study the estimated prevalence of AD in children between 0 and
14 years old was 8.6%. Topical corticosteroids are currently the favoured treatment
for AD. However, their use is limited. Tacrolimus ointment has a demonstrated
efficacy in the treatment of moderate and severe AD in children. Twice-weekly
maintenance treatment has been approved and the aim of this study was to carry
out a cost-effective analysis comparing maintenance with standard reactive treat-
ment with tacrolimus ointment from the perspective of the Spanish NHS.
METHODS:An economic model was developed to compare maintenance and stan-
dard treatment patients for a period of 12 months. For those patients who discon-
tinued tacrolimus treatment before 1 year, resource use associated with post-dis-
continuation treatment was identified through a specially convened Advisory
Board with a group of clinical experts. Costs in 2012 euros were assigned to the
resources identified. Utility values were also inputted into the model. Results were
expressed in terms of total costs and cost/QALY. RESULTS: For patients with mod-
erate or severe AD, twice-weekly maintenance treatment with tacrolimus oint-
ment was shown to be more effective compared with the standard treatment reg-
imen. In the case of severe AD, maintenance treatment was also less costly
compared with standard treatment (939 vs. 1,084€). For moderate AD, the ICER was
1,981€/QALY which is considerably lower than the acceptable cost-effective
threshold (30,000€/QALY). CONCLUSIONS: Twice-weekly maintenance treatment
with tacrolimus ointment compared with standard reactive treatment would ap-
pear to be cost-effective and an additional option for clinicians for the treatment of
children suffering with moderate and severe AD in Spain.
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OBJECTIVES: To estimate the cost-effectiveness of linezolid for the treatment of
methicillin resistant staphylococcus aureus (MRSA) confirmed complicated skin
and soft tissue infections (cSSTI) under the Brazilian private health care system
perspective. METHODS: A cost-effectiveness analysis was developed based in a
decision tree model to simulate 28 days of treatment. A systematic revision of the
literature was developed over the efficacy and safety of the use of linezolid, van-
comicin, daptomicin and teicoplanin in patients diagnosed with MRSA-confirmed
cSSTI. Efficacy data used to input the economic model is informed in a published
meta-analysis. In this meta-analysis pooled efficacy estimates were generated
from clinical and microbiological determinations of success for the MRSA-sub-
groups in cSSTI clinical trials using a Bayesian meta-analytic approach (treatment
success rate: linezolide-84.4%, vancomicin-74.7%, daptomicina-78.1% and teico-
planina-74.7%). The treatment duration was 14 days for each first line treatment
and more 14 days for the second line treatment. Patients in treatment with lin-
ezolid stay 8 days in the hospital using venous linezolid and complete the treat-
ment with oral linezolid during 6 days, based on Itani et al. 2010. Patients in treat-
ment with vancomicin, daptomicin or teicoplanin stay 14 days in the hospital using
venous drugs. The costs and consequences of the disease treatment were com-
puted for each treatment alternative. Only direct medical costs were considered
based in official Brazilian costs databases. RESULTS: The incremental cost-effec-
tiveness analysis demonstrated that linezolide is the most economically attractive
drug, with better efficacy and lower cost than the comparators. The total cost per
patient with linezolide, vancomicin, daptomicin and teicoplanina were BRL26,365/
USD12,861, BRL36,421/USD17,766, BRL37,651/USD18,366, BRL37,984/USD18,529, re-
spectively. (US$ 1  R$ 2.05). CONCLUSIONS: Linezolid is the best therapeutic
option, with better efficacy and safety and lower cost, versus vancomicin, daptomi-
cin and teicoplanin for the treatment of patients diagnosed with MRSA-confirmed
cSSTI under Brazilian private perspective.
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OBJECTIVES: To evaluate the cost-effectiveness of ranibizumab versus best sup-
portive care and grid laser photocoagulation therapy in patients with macular
edema (ME) secondary to branch or central retinal vein occlusion (BRVO or CRVO).
METHODS: A Markov model was developed to compare treatment with ranibi-
zumab to best supportive care (CRVO) and grid laser photocoagulation therapy
(BRVO) in patients with ME secondary to RVO. Data from the BRAVO and CRUISE
clinical trials were used to estimate transition probabilities between health states,
defined by best corrected visual acuity (BCVA) and the frequency of adverse events.
Costs and utilities from published sources were associated with each treatment
and the model health states, and these were combined to predict the incremental
costs and outcomes for a cohort treated over a lifetime horizon. The model in-
cluded the costs associated with fellow eye involvement and the cost of blindness.
A health system perspective in the UK was used. RESULTS: In CRVO, ranibizumab
lead to a gain of 0.539 QALYs at an incremental cost of £9,216. The incremental
cost-effectiveness ratio (ICER) was £17,103 per QALY. In BRVO, ranibizumab was
shown to produce a gain of 0.518 QALYs at an incremental cost of £8,141. The ICER
was £15,710 per QALY. Both results were below the threshold range of £20,000 to
£30,000 which is regarded as representing acceptable cost-effectiveness in the UK.
Probabilistic sensitivity analysis suggests that the probability of cost-effectiveness
for ranibizumab at a £20,000 threshold is 60% in CRVO and 57% in BRVO.
CONCLUSIONS: Ranibizumab is a cost-effective therapy for treating patients with
ME secondary to both BRVO and CRVO compared to current standard of care in the
UK (laser in BRVO and observation in CRVO).
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OCCLUSION IN CANADA
Haig J1, Lawrence D1, Barbeau M2, Blouin J2, Zaour N2
1OptumInsight, Burlington, ON, Canada, 2Novartis Pharmaceuticals Canada Inc., Dorval, QC,
Canada
OBJECTIVES: The value of ranibizumab as compared to standard care (laser pho-
tocoagulation in BRVO and observation in CRVO) was assessed within the frame-
work of a cost-utility analysis (CUA) from the Canadian health care and societal
perspectives. METHODS: Cost-utility of ranibizumab to the Canadian health care
system was analyzed using a Markov model that followed a cohort of 66 or 68 year
old patients (with BRVO or CRVO) over a lifetime time horizon. The model included
8 heath states as defined by best corrected visual acuity (BCVA) and 1 absorbing
state for death. Year 1 health state transitions were based on data from the BRAVO
and CRUISE trials, while year 2 transitions were based on data from the HORIZON
extension trial. From year 3 onwards, health state transitions were based on fixed
probabilities of maintaining or worsening BCVA. Health state utilities were derived
from both the literature and a Canadian utility study in RVO patients. Resource use
and costs were collected from clinical trials, published literature, and standard
Canadian sources. Costs and outcomes were discounted at 5% as recommended by
Canadian guidelines. RESULTS: From the health care perspective, patients receiv-
ing ranibizumab for BRVO accrued an additional 0.22 quality-adjusted life years
(QALYs) with a total estimated incremental cost of CAD$8,080, resulting in $36,725
per QALY gained. In CRVO, 0.41 QALYs and $11,466 were estimated, resulting in
$28,046 per QALY gained. From the societal perspective, considering costs related
to productivity losses, the analyses resulted in an incremental cost per QALY
gained of $11,266 for BRVO and $2,103 for CRVO. CONCLUSIONS: Compared to
standard care (laser photocoagulation in BRVO and observation in CRVO), ranibi-
zumab shows cost-effectiveness within commonly accepted cost per QALY thresh-
olds from both the health care and societal perspectives.
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OBJECTIVES:Quantify the cost effectiveness of treatments for macular edema (ME)
secondary to branch or central retinal vein occlusion (BRVO, CRVO) from U.S. pay-
er/societal perspectives. METHODS: A Markov model consisting of five visual acu-
ity (VA) health states and death was developed to quantify clinical outcomes, costs,
and quality-adjusted life-years (QALYs) associated with no treatment (observation)
or two-year treatment with ranibizumab monotherapy (six monthly injections; as
needed thereafter), laser photocoagulation (BRVO only), ranibizumab plus laser
(BRVO only), triamciniolone acetonide (CRVO only), or dexamethasone intravitreal
implant. Transition probabilities were based on patient-level data for ranibizumab
( laser) and published literature for the remaining alternatives. Health state-
specific costs and utilities were accrued for 13 years—approximate median survival
of an RVO patient—with costs and QALYs discounted 3% annually. Costs associ-
ated with treatment, adverse events, and impaired vision were expressed in 2011
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